Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition

A composition and drug technology, applied in the directions of drug combinations, active ingredients of heterocyclic compounds, antipyretics, etc.

Inactive Publication Date: 2014-08-13
BEIJING MEIBEITA DRUG RES
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024]However, currently commonly used antidepressant drugs have the disadvantages of slow onset of action, low effective rate and obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition
  • Medicinal composition
  • Medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0053] Reference Example Preparation of Morinda officinalis Oligosaccharide Extract

[0054] Take Morinda officinalis herbal medicine, pulverize it, pass through a 50-mesh sieve, extract the sieved product three times with petroleum ether; extract the dregs with ethanol three times, combine the extracts, evaporate to dryness under reduced pressure, and obtain the ethanol extract. The extract is dissolved in water and filtered; the filtrate is distributed and extracted in n-butanol and water to obtain a water extract. Adsorb the extract with activated carbon, elute with water until the detection of reducing sugar (sulfuric acid-phenol reaction) is negative, then elute with 10% to 70% ethanol solution, collect the oligosaccharide components, concentrate and dry, that is Morinda officinalis oligosaccharide extract. Its main components are inulin-type oligosaccharides measured by high performance liquid chromatography, including inulin-type trimeric oligosaccharides, inulin-type ...

Embodiment 2

[0059] Embodiment 2 Combination of Morinda officinalis oligosaccharide extract (I) and moclobemide

[0060] 2.1 Determination of antidepressant activity by mouse tail suspension test

[0061] Male ICR mice (SPF grade), weighing 18-22g, attach a clip to the center rope of the top plate of a 25×25×25cm tail-suspension box, clamp the mouse’s tail tip 1cm to make it hang upside down, and the head is 4-5cm away from the bottom of the box . A certain dose of Morinda officinalis oligosaccharide extract (I), moclobemide and the mixture prepared in different proportions are ground with 0.5% sodium carboxymethylcellulose solution to prepare a suspension for future use. Different doses of samples to be tested were orally administered 60 minutes before the experiment, and the tail was suspended for 6 minutes after administration, and the immobility time of the mice was accumulated for 4 minutes after the experiment. The results are shown in Table 2.

[0062] 2.2 Determination of antide...

Embodiment 3

[0067] The combination of embodiment 3 Morinda officinalis oligosaccharide extract (I) and imipramine

[0068] With reference to the method of embodiment 2, replace moclobemide with imipramine, measure the Morinda officinalis oligosaccharide extract (I) and imipramine by mouse tail suspension test method and mouse forced swimming test method Antidepressant activity of the composition. The results are shown in Table 3.

[0069] Table 3 Antidepressant activity of Morinda officinalis oligosaccharide extract and imipramine composition

[0070]

[0071] * : p<0.05 compared with the solvent control group

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition comprising Morinda officinalis oligosaccharide extract and a non-sugar antidepressant as active components. It is characterized in that the total content of inulin-type oligosaccharides in the extract of Morinda officinalis oligosaccharides is 50-70%, and the content of inulin-type pentameric oligosaccharides is 5-15%; non-sugar antidepressants include Monoamine oxidase inhibitor antidepressant drugs such as moclobemide, norepinephrine reuptake inhibitor antidepressant drugs such as imipramine, amitriptyline, maprotiline, doxepin, clomipa antidepressants such as fluoxetine, paroxetine, sertraline or citalopram, etc., or dual norepinephrine / selective serotonin Non-carbohydrate antidepressants of the reuptake inhibitor class, such as mirtazapine, duloxetine, venlafaxine, or desmethylvenlafaxine. The present invention also relates to the use of the pharmaceutical composition of Morinda officinalis oligosaccharide extract and a non-saccharide antidepressant drug as active ingredients in treating neuropsychiatric diseases such as depression, anxiety, and neurogenic pain.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition comprising Morinda officinalis oligosaccharide extract and a non-sugar antidepressant as active components. It is characterized in that the total content of inulin-type oligosaccharides in the extract of Morinda officinalis oligosaccharides is 50-70%, of which the content of inulin-type pentameric oligosaccharides is 5-15%; non-sugar antidepressants include Monoamine oxidase inhibitor antidepressant drugs such as moclobemide, norepinephrine reuptake inhibitor antidepressant drugs such as imipramine, amitriptyline, maprotiline, doxepin, clomipa antidepressants such as fluoxetine, paroxetine, sertraline or citalopram, etc., or norepinephrine / selective serotonin dual Non-carbohydrate antidepressants of the reuptake inhibitor class, such as mirtazapine, duloxetine, venlafaxine, or desmethylvenlafaxine. The present invention also relates to the use of the pharmaceutical composition of Morinda officinali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P25/22A61P25/24A61P25/00A61P29/00A61K36/746A61K31/5375A61K31/55A61K31/137A61K31/4525A61K31/135
Inventor 杨振强王建明
Owner BEIJING MEIBEITA DRUG RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com